

REMARKS

Claims 1-8, 15-17, and 19-28 are pending. Applicant herein has amended claims 1, 2, 5, 19, and 20 to reflect that the non-aminoglycoside moiety that alters the enzyme activity can, in the preferred embodiments now claimed, be a small molecule or a protein, polypeptide, or polypeptide derivative. Claims 6 and 7 have been amended to correct typographical errors.

The amendments made herein add no new matter and are fully supported by the specification and claims as originally filed. Notwithstanding these amendments, Applicant reserves the right to pursue subject matter no longer or not yet claimed in this or a related case.


Applicant respectfully requests reconsideration of the invention as now claimed. In particular, Applicant thanks the Examiner for acknowledging that the claims, before entry of the amendments made herein, have been enabled with regard to statins, protein, polypeptides, and derivative thereof. Applicant believes, however, that it would be more accurate to regard the invention as being enabled not only for these classes of compounds, but more generally for small molecules, nucleic acids, and nucleic acid derivatives, as well. Specifically, Applicant directs the Examiner's attention to the claims as they existed prior to entry of the above amendment, as well as to Examples 7-9 of the instant application, where a number of small molecule compounds of different chemical classes are described for use in the context of the invention. As will be appreciated, the specification generally defines "small molecules" in paragraphs 122-125 of the application as published. For this reason, Applicant respectfully submits that the claims as amended herein (as well as before entry of the above amendments) are indeed enabled by the specification and claims as originally filed. Accordingly, he respectfully requests withdrawal of the sole remaining rejection, which has been premised on the enablement requirement of 35 U.S.C. §112, first paragraph.

CONCLUSION

Applicant respectfully requests consideration of the pending claims, which Applicants believe are in condition for allowance. Of course, if any issue remains that can be dealt with appropriately without need for an additional formal action and response thereto, the Examiner is encouraged to telephone the undersigned at her earliest convenience at 858.350.9690 so that the same may be expeditiously resolved.

Dated: 13 DEC 2004

Respectfully submitted,

By: 

Daniel M. Chambers
Attorney for Applicant
BioTechnology Law Group
Reg. No. 34,561